- Created on the 11 May, 2017.
Human CA 19-9 ELISA kit can be used for analysing in vitro quantitative concentrations of cancer antigen 19-9 (CA 19-9, carbohydrate antigen 19-9, CA19-9, sialylated Lewis A antigen) in human serum and plasma (EDTA and heparin). This assay has a minimum sensitivity limit of 0.2 U/ml.
Cancer antigen 19-9 can also be known as tumor sialylated Lewis A antigen, carbohydrate antigen 19-9, CA19-9 or CA 19-9, it is a tumor marker or a tumor-associated antigen which is the predominant marker used in pancreatic cancer management. CA 19-9 was first discovered in the serum of colon and pancreatic cancer patients and elevated levels are often found in the serum samples of patients having cancer of the pancreato-biliary system (this includes pancreas, biliary tract and gallbladder). In addition, elevated levels of CA 19-9 are also identified in a number of other malignancies (for example lung and a number of other gastrointestinal cancers such as esophageal, colorectal and hepatocellular carcinoma). Apart from cancer, CA 19-9 levels are elevated in cirrhosis, pancreatitis and diseases of the bile ducts. It is important to take in to account that patients that are genotypically negative for the Lewis blood group antigen, will not have the ability to produce the CA 19-9 antigen even when there is malignant tissue present. The following CA19-9 ELISA kit is ideal for analysing many types of diagnostic applications.
The minimum detection sensitivity level of human cancer antigen 19-9 (CA19-9, sialylated Lewis A antigen or carbohydrate antigen 19-9) using current human CA 19-9 ELISA kit was 0.2 U/ml. The dynamic range for this assay is 15.0 – 240.0 U/ml.
- CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. (2015) 867: 247-60. Review. Scarà S., et al.
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. (2007) 33 (3): 266-70. Review. Goonetilleke K.S. and Siriwardena A.K.
- Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. (2012) 18 (6): 530-8. Review. Fong Z.V. and Winter J.M.
- Serum tumor markers in bile duct cancer–a review. Biomarkers. (2014) 19 (6): 437-43. Review. Grunnet M. and Mau-Sørensen M.
- CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. (1998) 35 (Pt 3): 364-70. Review. Duffy M.J.
- Full Name: Cancer Antigen 19-9 (CA 19-9) ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum
- Sensitivity: 0.2 U/ml